2024-03-29T14:36:46Z
https://niigata-u.repo.nii.ac.jp/oai
oai:niigata-u.repo.nii.ac.jp:00019252
2022-12-15T03:50:12Z
453:456
471:537:538:1148
The Effect of New Antiplatelet Therapy on Reocclusion after Aorto-Coronary Bypass Surgery : 3rd Report : Long-Term Results and Conclusions
新しい抗血小板療法による冠動脈バイパス術後の閉塞防止の研究 : 第三報 : 長期成績および総括
新しい抗血小板療法による冠動脈バイパス術後の閉塞防止の研究 : 第三報 : 長期成績および総括
藤田, 俊夫
119954
相沢, 正樹
119955
山添, 優
119956
和泉, 徹
119957
柴田, 昭
119958
服部, 晃
119959
林, 純一
119960
江口, 昭治
119961
A-C bypass 術
aspirin
ticlopidine
graft 閉塞率
抗血小板療法
The present study was aimed to elucidate the effect of antiplatelet therapy on patency of saphenous vein graft after aorto-coronary bypass surgery. We divided the 96 patients who underwent aorto-coronary bypass surgery into two groups: GATS (Graft Aspirin Ticlopidine Study) group and control group. And the occlusion rate was assessed both at the time of one month and 12 months after bypass surgery. All patients received warfarin, and the patients in GATS group received aspirin (10~50mg) and ticlopidine (100~200mg). The patients in control group received only warfarin. In GATS group, the early occlusion rate was 14.6% and the late occlusion rate was 28.8%. On the other hand, the early occlusion rate was 19.2% and the late occlusion rate was 28.8% in control group. There was no significant difference in the occlusion rate between GATS group and control group. In patients whose graft flow was under 50ml/min, the occlusion rate in GATS group was 10.8%, but in control group was 32.1% at the time of one month. These results indicate that antiplatelet therapy after A-C bypass surgery may have no effect on whole occlusion rate, but may have a little effect on the occlusion rate in low graft flow group. It may be important that when we should start the antiplatelet therapy after aortocoronary bypass surgery.
departmental bulletin paper
新潟医学会
1994-07
application/pdf
新潟医学会雑誌
7
108
532
539
新潟医学会雑誌
AN00182415
00290440
https://niigata-u.repo.nii.ac.jp/record/19252/files/108(7)_532-539.pdf
jpn